NeurAegis recently reported results with its selective calpain-2 inhibitor, NA 101, on a mouse model of acute glaucoma in a publication in Neurobiology of Disease. NeurAegis scientists have identified a critical enzyme, calpain-2, which is activated early following increased IOP and is responsible for producing neuronal death. The company also found that a single systemic or intraocular injection of a selective calpain-2 inhibitor given 2 hours following increased IOP, prevented RGC death and loss of vision in mice. These results suggest the possibility of developing selective calpain-2 inhibitors for the treatment of acute glaucoma, according to a company news release.
The company is currently pursuing the preclinical studies required to bring a selective calpain-2 inhibitor to the clinic for the treatment of acute glaucoma within the next 2-3 years.
The study can be found here: https://www.sciencedirect.com/science/article/pii/S0969996116301012.